Clinical Trials Logo

Internal Hemorrhoids clinical trials

View clinical trials related to Internal Hemorrhoids.

Filter by:
  • None
  • Page 1

NCT ID: NCT03335774 Completed - Clinical trials for Internal Hemorrhoids

Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in Treatment of Internal Hemorrhoids

Start date: February 12, 2019
Phase: Phase 2
Study type: Interventional

A randomized, double-blind, placebo-controlled, multicenter, parallel group study of the safety and efficacy of Hydrocortisone Acetate Suppositories, 25 mg compared to placebo suppositories in the treatment of symptomatic internal hemorrhoids.

NCT ID: NCT01913158 Completed - Clinical trials for Internal Hemorrhoids

Safety and Efficacy Study of Anucort HC TM 25mg Rectal Suppositories to Treat Symptomatic Internal Hemorrhoids

Start date: October 2013
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine the safety and efficacy of G&W Laboratories' Anucort HC TM (Hydrocortisone Acetate) 25mg Rectal Suppositories in subjects with internal hemorrhoidal symptoms.

NCT ID: NCT01533363 Completed - Clinical trials for Internal Hemorrhoids

Study About Patient Comfort and Long-term Outcome After Stapled Hemorrhoidopexy

Start date: July 2000
Phase: Phase 3
Study type: Interventional

The purpose of this study was to determine the influence on Patient comfort after Stapled Hemorrhoidopexy versus Milligan Morgan (two surgical procedures)in third degree circular hemorrhoids.

NCT ID: NCT01355874 Terminated - Clinical trials for Internal Hemorrhoids

Efficacy and Safety Study to Treat Subjects With Symptomatic Internal Hemorrhoids

VEN309
Start date: July 2011
Phase: Phase 3
Study type: Interventional

Primary Objective: To evaluate the effect of iferanserin ointment on cessation of bleeding when administered intra-anally twice daily (BID) for 7 or 14 days in subjects with symptomatic internal hemorrhoids. Methodology: Double-Blind: Phase 3, multicenter, double-blind, randomized, parallel group, placebo-controlled part of the study. Extension: Multicenter, open-label part of the study. Study Treatment Duration: Double-Blind: 28 days (14-day treatment period and a 14-day follow-up period). Extension: 12 months (open-label part of the study in which there will be a scheduled visit every three months. Subjects who have recurrence(s) of their symptomatic internal hemorrhoids will be treated with open-label iferanserin for 7 days followed by a 21-day follow-up period). Criteria for Evaluation: Primary Endpoint: The primary endpoint is the cessation of bleeding by the end of Day 7 that persists for the remainder of the treatment period (through Day 14).